NASDAQ:DTIL

Precision Biosciences Stock News

Healthcare > Biotechnology

Buy DTIL

*Your capital is at risk

$6.04

-0.280 (-4.43%)

At Close: Jun 03, 2026

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

06:12pm, Tuesday, 17'th Mar 2026

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

09:15am, Thursday, 12'th Mar 2026

Precision BioSciences (DTIL) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $3.2 per share a year ag

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

07:00am, Thursday, 12'th Mar 2026

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

07:01am, Wednesday, 11'th Mar 2026

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

07:01am, Tuesday, 10'th Mar 2026

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

04:15pm, Monday, 09'th Mar 2026

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

07:01am, Monday, 09'th Mar 2026

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

07:01am, Monday, 02'nd Mar 2026

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

07:01am, Wednesday, 18'th Feb 2026

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

07:01am, Wednesday, 11'th Feb 2026

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

07:01am, Monday, 12'th Jan 2026

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

03:40am, Monday, 29'th Dec 2025

Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming fo

Cullinan Therapeutics (NASDAQ:CGEM) versus Precision BioSciences (NASDAQ:DTIL) Critical Analysis

01:12am, Monday, 29'th Dec 2025

Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) and Precision BioSciences (NASDAQ: DTIL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare t

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

07:00am, Tuesday, 23'rd Dec 2025

Precision Biosciences: Still Swinging And Finally Drawing Blood

06:38am, Thursday, 04'th Dec 2025

Precision BioSciences is advancing a de-risked gene-editing pipeline with promising clinical data and multi-year cash runway. PBGENE-HBV shows compelling early efficacy and safety, positioning DTIL fo

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by